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Abstract
Background: Infertility is characterized by the inability to obtain a successful pregnancy
after 6 months or more with unprotected and regular intercourse. In developing
countries, the incidence of infertility is 2%. The causes of infertility could be male factor
or female factor, or mixed factor.
Objective: This study was conducted with the aim of comparison the ovarian response
to letrozole alone and letrozole plus dexamethasone in infertile women with poly cystic
ovarian disease (PCOS).
Materials and Methods: This randomized clinical trial was conducted on 120 infertile
women with PCOS referred to Ali-Ebne-Abitaleb hospital, Zahedan, Iran from February
to August 2017 into two groups: group I received letrozole alone and group II
recived letrozole plus dexamethasone. The endometrial thickness, follicle diameter,
and ovulation were evaluated and compared by ultrasound on days 12 to 14.
Results: The mean thickness of endometrium was not different between two groups.
Pregnancy rate was 8% in letrozole group and 23% in Letrozole plus Dexamethasone
(p = 0.024). Also, the mean diameter of follicles in two groups were not statistically
significant.
Conclusion: Overall, this study showed that dexamethasone may increase pregnancy
rate.
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1. Introduction
Infertility is non-pregnancy after one year or
more of unprotected sexual intercourse (1, 2).
according to a large systematic analysis (2012),
approximately 45-52 million couples (on average
48.5 million couples) have this problem all over the
world (2).
Female causes are the most common causes
of infertility. Among these factors, ovulatory
disorders are the most common causes of female
infertility.
Induction ovulation is the main treatment for
ovulation disorders, and letrozole, as the first-
line treatment for induction ovulation, may be as
effective as clomiphene. In different studies, the
success rate of letrozole in induction ovulation was
70-84% and the pregnancy rate was reported to be
27-20% (3, 4).
The weak response of the ovary to the
gonadotropins is one of the problems in
assisted reproductive techniques, which occurs
in 9-26% of cycles. The ovarian response to
stimulation of gonadotropins is regulated by
an insulin-like growth factor-1. Glucocorticoids
can be indirectly associated with increasing
in serum levels of growth hormone and IGF-1.
Consequently, increasing of IGF-1 concentration
in follicular fluid is effective in improving the
responses of weak responders. Dexamethasone
improves ovulation by reducing the effect of
adrenal androgens on follicular growth (5-
7).
The aim of this study was to evaluate and
compare the response of ovaries to letrozole
alone and dexamethasone with letrozole in infertile
women with poly cystic ovarian syndrome (PCOS).
2. Materials and Methods
This randomized clinical trial was conducted
on 120 infertile women with PCOS, aged between
18-39 years, referred to infertility clinic of Ali-Ebne-
Abitaleb hospital, Zahedan, Iran from February to
August 2017 into two groups (n = 60/each): group
I received letrozole alone and group II recived
letrozole plus dexamethasone (Figure 1). The study
was done with the block randomization method
with 10 blocks and no blinding was performed.
The inclusion criteria were women with PCOS
diagnosis and primary infertility, normal semen
analysis of husband, and age between 18 and 39
years. Our exclusion criteria were co-administration
of corticosteroid, endocrine disorders (such
as thyroid disorders, high prolactin due to
prolactinoma), and the history of ovarian surgery.
Letrozole (Iran Hormon company, Iran) was given
in each group at the dose of 5mg/day from the third
to seventh day of the menstrual cycle for 5 days,
and (Zahravi Pharma Co., Iran) was given at a dose
of 0.5 mg / day with letrozole from day 4 to 15 orally.
To determine the thickness of the endometrium,
follicular diameter, and the evidence of ovulation,
a vaginal ultrasound scan was performed on day
12-14 by an infertility fellowship.
Figure 1. The COSORT flowchart of the study (letrozole vs letrozole plus dexamethasone).
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2.1. Ethical consideration
Written Informed consent was obtained
from all participants in this study. The study
has been approved by Zahedan University
of Medical Sciences ethical committee (code:
IR.ZAUMS.REC.1396.343)
2.2. Statistical analysis
Data were analyzed using SPSS software
(Statistical Package for the Social Sciences),
version 22, and Chi-square and Independent
t tests. P < 0.05 was considered statistically
significant.
3. Results
The results of this study showed that the
mean thickness of endometrium in the two
groups was not statistically significant. Based
on Chi-square test, the frequency of pregnancy
in the letrozole group plus dexamethasone was
significantly higher than letrozole alone group
(23% vs. 8%, respectively; p = 0.024). Also, the
mean diameter of follicles in two groups were not
statistically significant (Table I).
Table I. Comparison of mean endometrial thickness, diameter of follicles, and pregnancy rate in two study groups (n = 60/each)
Variables Group I (Letrozole) Group II (Letrozole +
Dexametasone)
P-value
Endometrial thickness (mm)** 7.4 ± 2.2 8 ± 2.3 0.11𝑎
Pregnancy rate (%)** 5 (%8) 14 (%23) 0.024𝑏
Diameter of follicles (Right
ovary) (mm)*
16.4 ± 3.3 16.9 ± 3.3 0.465𝑎
Diameter of follicles (Left
ovary) (mm)*
16.2 ± 3 16.2 ± 3 0.821𝑎
* Data presented as Mean ± SD, ** Data presented as n(%), a: Independent t test, b: Chi-square
4. Discussion
The aim of this study was to investigate and
compare the response of ovaries to letrozole plus
dexamethasone with letrozole alone in infertile
women with PCOS. The results showed that
the prevalence of pregnancy in dexamethasone
plus letrozole group was significantly higher than
letrozole alone. However, the thickness of the
endometrium did not differ significantly between
the two groups. Farzaneh and co-workers showed
the degree of ovulation and also the pregnancy
rate in the letrozole group was significantly higher
than the clomiphene citrate group (2, 3).
A study by Al-Shaikh and colleagues examined
the effect of prednisolone with clomiphene citrate
on induction of ovulation in women with PCOS
resistant to clomiphene citrate. In this study, the
mean thickness of the endometrium as well as
ovulation rate and frequency of fertility in the
group receiving prednisolone plus clomiphene
citrate was significantly higher than clomiphene
citrate alone (5). Another study by Begum and
others in Bangladesh (2012) examined the effect
of dexamethasone plus letrozole in women with
PCOS for infertility treatment. In this study 470
women were prescribed letrozole with doses 5
mg / day for 5 days that 280 women who did
not respond to letrozole treatment were treated
with letrozole plus dexamethasone (0.5 mg/day
between the second and the 10th day) in the next
cycle. Their results showed that 65% of women
https://doi.org/10.18502/ijrm.v13i4.6893 Page 309
International Journal of Reproductive BioMedicine Farzaneh and Afshar
receiving dexamethasone, had ovulation signs in
trans vaginal sonography in this cycle and 33%
were pregnant (6). that conducted by Ashrafi and
co-workers in Tehran (2014) to evaluate the effect of
dexamethasone on ovarian response in 72 women
over 35 years old in IVF cycle, reported that the
mean count of oocytes in the dexamethasone
group and the placebo group, was not significant.
Also, the percentage of embryos and the mean
count of transferred embryos in the two groups
was not statistically significantl, but the number
of human menopausal gonadotropin injections in
the dexamethasone group was significantly low
(7). Another study by Shabana and others in
Egypt in 2017 examined and compared the effects
of letrozole plus dexamethasone vs clomiphene
citrate with dexamethasone in 60 women with
PCOS (30 in each group) and reported that the
mean thickness of the endometrium and also the
mean diameter of the follicles in the letrozole
group with dexamethasone were significantly
higher than those receiving clomiphene citrate
plus dexamethasone (8). Comparing the results
of various studies in this field, we conclude
that the use of dexamethasone increases ovarian
responsiveness to ovulation-inducing drugs and
also increases the fertility rate.
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